Global Rituximab Market, By Route of Administration (Subcutaneous, Intravenous, Parenteral), Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Rituximab Market
The rituximab market is expected to witness market growth at a rate of 6.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on rituximab market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of rituximab market.
Rituximab refer to the type of biosimilars that are utilized as a single agent or in combination with chemotherapy for treating diseases such as non-Hodgkin lymphoma (NHL), granulomatosis with polyangiitis (GPA), chronic lymphocytic leukemia (CLL), and microscopic polyangiitis (MPA).
The rise in the geriatric population across the globe acts as one of the major factors driving the growth of rituximab market. The increase in demand for biosimilar drugs due to their cost-effectiveness and rise in the prevalence of non-Hodgkin's lymphoma (NHL) among population accelerate the market growth. The development in commercial pipelines and increase in government initiatives towards the development of the product further influence the market. Additionally, supportive government legislation, surge in healthcare expenditure, abbreviated regulatory approval process, development in technology, surge in healthcare expenditure and increase in biopharmaceutical R&D expenditure positively affect the rituximab market. Furthermore, research on new indications and patent expiry of biologics extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, high cost associated with rituximab and complexities in manufacturing are expected to obstruct the market growth. Excess competition among manufacturers and resistance from biologics manufacturers are projected to challenge the rituximab market in the forecast period of 2022-2029.
This rituximab market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info rituximab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Rituximab Market Scope and Market Size
The rituximab market is segmented on the basis of route of administration, application and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of route of administration, the rituximab market is segmented into subcutaneous, intravenous and parenteral.
- On the basis of application, the rituximab market is segmented into Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and others.
- On the basis of distribution channel, the rituximab market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
Rituximab Market Country Level Analysis
The rituximab market is analyzed and market size information is provided by country, route of administration, application and distribution channel as referenced above.
The countries covered in the global rituximab market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the rituximab market due to the presence of developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the increase in the research and development activities in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The rituximab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Rituximab Market Share Analysis
The rituximab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related rituximab market.
Some of the major players operating in the rituximab market are Amgen Inc, Pfizer Inc, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc, and Biocad, and others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL RITUXIMAB MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL RITUXIMAB SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL RITUXIMAB MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5. INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6. EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7. MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8. REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9. PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10. MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 DRUG DOSAGES FORM
10.7 DOSAGES AVAILABILITY
10.8 PACKAGING TYPE
10.9 DRUG ROUTE OF ADMINISTRATION
10.10 DOSING FREQUENCY
10.11 DRUG INSIGHT
10.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.12.1 FORECAST MARKET OUTLOOK
10.12.2 CROSS COMPETITION
10.12.3 THERAPEUTIC PORTFOLIO
10.12.4 CURRENT DEVELOPMENT SCENARIO
11. MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12. R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13. MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14. GLOBAL RITUXIMAB MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 BRANDED
14.2.1 RITUXAN
14.2.2 MABALL
14.2.3 MABTAS
14.2.4 REDITUX RA
14.2.5 CYTOMAB
14.2.6 OTHERS
14.3 BIOSIMILARS
15. GLOBAL RITUXIMAB MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 SUBCUTANEOUS
15.3 INTRAVENOUS
16. GLOBAL RITUXIMAB MARKET, BY APPLICATION
16.1 OVERVIEW
16.2 CANCER
16.2.1 NON-HODGKIN LYMPHOMA (NHL)
16.2.2 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
16.2.3 OTHER CANCER TYPES
16.3 AUTOIMMUNE DISEASES
16.3.1 RHEUMATOID ARTHRITIS
16.3.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
16.3.3 OTHER AUTOIMMUNE DISEASES
17. GLOBAL RITUXIMAB MARKET, BY DOSAGE
17.1 OVERVIEW
17.2 BELOW 50 MG
17.3 100 MG
17.4 200 MG
17.5 300 MG
17.6 400 MG AND ABOVE
18. GLOBAL RITUXIMAB MARKET, BY AGE GROUP
18.1 OVERVIEW
18.2 PAEDIATRICS
18.3 ADULTS
18.4 ELDERLY
19. GLOBAL RITUXIMAB MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.3 FEMALE
20. GLOBAL RITUXIMAB MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITAL
20.3 CANCER SPECIALTY CENTERS
20.4 ACADEMIC AND RESEARHC INSTITUTES
20.5 OTHERS
21. GLOBAL RITUXIMAB MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 HOSPITAL PHARMACIES
21.3.2 RETAIL PHARMACIES
21.3.3 ONLINE PHARMACIES
21.4 OTHERS
22. GLOBAL RITUXIMAB MARKET, SWOT AND DBMR ANALYSIS
23. GLOBAL RITUXIMAB MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24. GLOBAL RITUXIMAB MARKET, BY REGION
Global RITUXIMAB Market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 U.K.
24.2.3 ITALY
24.2.4 FRANCE
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 SWITZERLAND
24.2.8 TURKEY
24.2.9 BELGIUM
24.2.10 NETHERLANDS
24.2.11 DENMARK
24.2.12 SWEDEN
24.2.13 POLAND
24.2.14 NORWAY
24.2.15 FINLAND
24.2.16 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 SINGAPORE
24.3.6 THAILAND
24.3.7 INDONESIA
24.3.8 MALAYSIA
24.3.9 PHILIPPINES
24.3.10 AUSTRALIA
24.3.11 NEW ZEALAND
24.3.12 VIETNAM
24.3.13 TAIWAN
24.3.14 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 EGYPT
24.5.3 BAHRAIN
24.5.4 UNITED ARAB EMIRATES
24.5.5 KUWAIT
24.5.6 OMAN
24.5.7 QATAR
24.5.8 SAUDI ARABIA
24.5.9 REST OF MEA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25. GLOBAL RITUXIMAB MARKET, COMPANY PROFILE
25.1 PFIZER INC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 GENENTECH USA, INC
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 HETERO HEALTHCARE LIMITED.
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 INTAS PHARMACEUTICALS LTD
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 AMGEN INC
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 CELLTRION HEALTHCARE CO.,LTD.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 NOVARTIS AG
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 RELIANCE LIFE SCIENCES
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 F. HOFFMANN-LA ROCHE LTD
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.10 BIOSPACE.COM.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 TEVA PHARMACEUTICALS USA, INC
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 BIOCAD
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 SHANGHAI HENLIUS BIOTECH, INC
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 CADILA PHARMACEUTICALS
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 NAPP PHARMACEUTICALS
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 MUNDIPHARMA INTERNATIONAL.
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 MABION S.A
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 MABXIENCE
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
26. RELATED REPORTS
27. CONCLUSION
28. QUESTIONNAIRE
29. ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
